Last reviewed · How we verify
NCT06221644
Synapse Alterations in MSA Patients
trial testing [18F]SynVesT-1 PET/CT in Multiple System Atrophy in 90 participants. Completed in 25 November 2022.
30 October 2022
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 April 2022 |
| Primary completion | 30 October 2022 |
| Estimated completion | 25 November 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- [18F]SynVesT-1 PET/CT
Conditions studied
- Multiple System Atrophy — all drugs for Multiple System Atrophy →
Sponsor
Xiangya Hospital of Central South University
Who can join
18 and older, any sex, with Multiple System Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Synaptic loss has been implicated in various neurodegenerative conditions, yet its understanding in multiple system atrophy (MSA) remains limited. The aim of this study was to examine spatial synaptic density alterations in MSA patients and evaluate the potential of \[18F\]SynVesT-1 PET as an imaging biomarker for MSA in both diagnosis and monitoring disease severity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06221644
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple System Atrophy
Currently open trials in the same condition.
- NCT07197866 — An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy · Phase 2 · recruiting
- NCT06868628 — A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) · Phase 2 · recruiting
- NCT07353463 — Shanghai Clinical Cohort - Parkinson's Disease (Reserve) · recruiting
- NCT06848231 — A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy · Phase 2 · recruiting
- NCT06683365 — Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies · Phase 1 · recruiting
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06221644 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 25 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06221644.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing